NI202000051A - Anticuerpos monoclonales y métodos para utilizar los mismos. - Google Patents

Anticuerpos monoclonales y métodos para utilizar los mismos.

Info

Publication number
NI202000051A
NI202000051A NI202000051A NI202000051A NI202000051A NI 202000051 A NI202000051 A NI 202000051A NI 202000051 A NI202000051 A NI 202000051A NI 202000051 A NI202000051 A NI 202000051A NI 202000051 A NI202000051 A NI 202000051A
Authority
NI
Nicaragua
Prior art keywords
cell receptors
family
antibody
monoclonal antibodies
trbv9 family
Prior art date
Application number
NI202000051A
Other languages
English (en)
Inventor
Vladimirovna Britanova Olga
Aleksandrovic Izraelson Mark
Anatolievich Lukyanov Sergey
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of NI202000051A publication Critical patent/NI202000051A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se relaciona con anticuerpos monoclonales que se unen de manera específicamente a la familia TRBV9 del receptor de las células T humanas. La invención también se refiere a un ácido nucleico que codifica dicho anticuerpo o un fragmento de unión a antígeno del mismo, a un vector de expresión, a un método para producir el anticuerpo, y al uso de dicho anticuerpo para tratar enfermedades o trastornos asociados con el familia de receptores de células T humanas. La invención está dirigida a producir anticuerpos que pueden usarse para eliminar células T que portan receptores de células T de la familia TRBV9, en particular para tratar espondilitis anquilosante, enfermedad celíaca y cánceres de sangre, en la patogénesis de los cuales receptores de células T de La familia TRBV9 está involucrada.
NI202000051A 2017-12-25 2020-06-25 Anticuerpos monoclonales y métodos para utilizar los mismos. NI202000051A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2017145662A RU2694412C9 (ru) 2017-12-25 2017-12-25 Моноклональные антитела и способы их применения

Publications (1)

Publication Number Publication Date
NI202000051A true NI202000051A (es) 2021-12-16

Family

ID=67002533

Family Applications (1)

Application Number Title Priority Date Filing Date
NI202000051A NI202000051A (es) 2017-12-25 2020-06-25 Anticuerpos monoclonales y métodos para utilizar los mismos.

Country Status (20)

Country Link
US (2) US11597767B2 (es)
EP (1) EP3733705A4 (es)
JP (1) JP7339948B2 (es)
KR (1) KR20200103774A (es)
CN (1) CN111801354B (es)
AU (1) AU2018398341A1 (es)
BR (1) BR112020012959A2 (es)
CA (1) CA3086849A1 (es)
CL (1) CL2020001726A1 (es)
CR (1) CR20200324A (es)
EA (1) EA202091569A1 (es)
EC (1) ECSP20039728A (es)
JO (1) JOP20200161A1 (es)
MA (1) MA50128B1 (es)
MX (1) MX2020006736A (es)
NI (1) NI202000051A (es)
PH (1) PH12020551012A1 (es)
RU (1) RU2694412C9 (es)
WO (1) WO2019132738A1 (es)
ZA (1) ZA202003858B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2694412C9 (ru) * 2017-12-25 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Моноклональные антитела и способы их применения
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
RU2711871C1 (ru) 2018-12-25 2020-01-23 Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Моноклональные антитела, которые специфически связываются с участком бета цепи семейства TRBV-9 Т-клеточного рецептора человека, и способы их применения
RU2712251C1 (ru) * 2018-12-25 2020-01-27 Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения
WO2024039268A1 (ru) * 2022-08-18 2024-02-22 Акционерное общество "БИОКАД" Способ лечения заболевания, опосредованного т-лимфоцитами

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223426A (en) 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
US5766947A (en) 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
KR20120044941A (ko) 2009-06-25 2012-05-08 프레드 헛친슨 켄서 리서치 센터 적응 면역의 측정방법
EP3202784A1 (en) * 2016-02-08 2017-08-09 Polybiocept AB T-cell receptor sequences for active immunotherapy
JP6952225B2 (ja) * 2016-03-18 2021-10-20 北海道公立大学法人 札幌医科大学 Ｔ細胞レセプターとその利用
CA3022129A1 (en) 2016-06-17 2017-12-21 Medigene Immunotherapies Gmbh T cell receptors and uses thereof
RU2694412C9 (ru) * 2017-12-25 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Моноклональные антитела и способы их применения

Also Published As

Publication number Publication date
PH12020551012A1 (en) 2021-09-01
RU2017145662A (ru) 2019-06-25
EP3733705A4 (en) 2021-09-01
CN111801354A (zh) 2020-10-20
JP7339948B2 (ja) 2023-09-06
WO2019132738A1 (ru) 2019-07-04
BR112020012959A2 (pt) 2020-12-01
RU2694412C2 (ru) 2019-07-12
ECSP20039728A (es) 2020-08-31
KR20200103774A (ko) 2020-09-02
EP3733705A1 (en) 2020-11-04
EA202091569A1 (ru) 2021-02-11
CA3086849A1 (en) 2019-07-04
JP2021509274A (ja) 2021-03-25
MA50128B1 (fr) 2022-09-30
MX2020006736A (es) 2020-08-24
US11597767B2 (en) 2023-03-07
RU2017145662A3 (es) 2019-06-25
JOP20200161A1 (ar) 2022-10-30
US20200332003A1 (en) 2020-10-22
CN111801354B (zh) 2024-08-30
CL2020001726A1 (es) 2021-03-05
US20230357396A1 (en) 2023-11-09
CR20200324A (es) 2020-10-08
MA50128A1 (fr) 2021-07-29
AU2018398341A1 (en) 2020-07-30
RU2694412C9 (ru) 2019-09-18
ZA202003858B (en) 2021-07-28

Similar Documents

Publication Publication Date Title
NI202000051A (es) Anticuerpos monoclonales y métodos para utilizar los mismos.
DOP2018000212A (es) Moléculas de unión a bcma y métodos de uso de las mismas
CL2018002490A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866)
BR112017014551A2 (pt) ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit?
CO2021009693A2 (es) Proteínas de unión a antígeno del receptor gamma anti-il2
CR20190066A (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
CO2018003852A2 (es) Proteínas de unión a antigeno que activan el receptor de leptina
BR112018000696A2 (pt) ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
CL2021001704A1 (es) Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso.
BR112016010513A2 (pt) anticorpos anti-il-17, método de produção e uso dos mesmos
PE20150642A1 (es) Proteinas fijadoras de antigeno antagonistas del receptor de accion dual y sus usos
PE20161210A1 (es) Anticuerpos anti-mcam y metodos de uso asociados
UY37683A (es) Anticuerpo monoclonal anti-pd-l1 monoclonal
CO2018004930A2 (es) Moléculas de unión específicas para asct2
EA201992460A1 (ru) Антитела-агонисты btla и их применение
EA202191666A1 (ru) Антитела к il-27 и их применение
CO2021009689A2 (es) Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso.
CL2019000426A1 (es) Anticuerpo o un fragmento de unión a antígeno del mismo, capaz de unirse a un receptor humano de interleucina-6.
BR112015027388A2 (pt) Anticorpo monoclonal ou porção do mesmo que se liga a cxcr5, seu método de produção e seu uso, polinucleotídeos, vetores de expressão, célula hospedeira, e composição farmacêutica
ECSP20024551A (es) ANTICUERPO MONOCLONAL PARA IL-5Ra
AR115992A2 (es) Proteínas de unión a antígeno que activan el receptor de leptina
AR119964A2 (es) Anticuerpos anti-cd123 y conjugados y derivados de estos
AR106658A1 (es) Moléculas de unión específicas de asct2 y sus usos
EA201990543A1 (ru) Композиции и способы репрограммирования т-клеточных рецепторов с помощью гибридных белков
CR20150030A (es) Proteínas fijadoras de antígeno antagonistas del receptor de acción dual y sus usos